Serum glutathione and 4-hydroxynonenal profiles in relation to diabetic kidney disease severity and progression: a multicenter cross-sectional study and a longitudinal cohort

Background Diabetic kidney disease (DKD) is clinically heterogeneous. We assessed whether circulating glutathione (GSH) and 4-hydroxynonenal (4-HNE) were associated with DKD severity and subsequent progression. Methods We analyzed a multicenter cross-sectional cohort of 377 adults with DKD and a single-center ambidirectional cohort of 156 adults with early-stage DKD. Serum GSH and 4-HNE were measured using commercial assays. Progression was assessed using Kaplan-Meier methods and Cox models adjusted for baseline estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). Exploratory within-cohort discrimination was evaluated using 24-month time-dependent receiver operating characteristic (ROC) curves and bootstrap assessment of calibration and incremental discrimination. Results GSH was lowest and 4-HNE highest in advanced-stage DKD (both P < 0.001 for association with ordered stage). During a mean time to event or censoring of 25.18 ± 11.43 months, 29 participants (18.6%) progressed. Low GSH (≤10.30 μmol/L; hazard ratio [HR], 3.19; 95% CI, 1.17–8.67) and high 4-HNE (>495.19 pg/mL; HR, 5.01; 95% CI, 2.03–12.35) were associated with progression, with directionally consistent continuous analyses. The combined biomarker score had a 24-month area under the curve (AUC) of 0.820. Adding both biomarkers to eGFR and UACR increased the optimism-corrected Harrell’s concordance index (C-index) from 0.689 to 0.821 (corrected increment, 0.133). Conclusions Lower GSH and higher 4-HNE were associated with progression in early-stage DKD. GSH varied nonmonotonically across severity categories, with the lowest GSH and highest 4-HNE in advanced-stage disease. Joint assessment improved discrimination within this cohort, suggesting that the two biomarkers provide complementary information for assessing progression risk in early-stage DKD.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-13
DOI
https://doi.org/10.3389/fendo.2026.1966993
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serum glutathione and 4-hydroxynonenal profiles in relation to diabetic kidney disease severity and progression: a multicenter cross-sectional study and a longitudinal cohort

Shunxuan Xue, Chunyao Li, Weiwei Sun, Jiale Zhang et al.
3 links
Frontiers in Endocrinology
Chronic Kidney Disease and Diabetes
article

Serum glutathione and 4-hydroxynonenal profiles in relation to diabetic kidney disease severity and progression: a multicenter cross-sectional study and a longitudinal cohort

Shunxuan Xue, Chunyao Li, Weiwei Sun, Jiale Zhang, Shuyu Pang
article en

Abstract

Background Diabetic kidney disease (DKD) is clinically heterogeneous. We assessed whether circulating glutathione (GSH) and 4-hydroxynonenal (4-HNE) were associated with DKD severity and subsequent progression. Methods We analyzed a multicenter cross-sectional cohort of 377 adults with DKD and a single-center ambidirectional cohort of 156 adults with early-stage DKD. Serum GSH and 4-HNE were measured using commercial assays. Progression was assessed using Kaplan-Meier methods and Cox models adjusted for baseline estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). Exploratory within-cohort discrimination was evaluated using 24-month time-dependent receiver operating characteristic (ROC) curves and bootstrap assessment of calibration and incremental discrimination. Results GSH was lowest and 4-HNE highest in advanced-stage DKD (both P < 0.001 for association with ordered stage). During a mean time to event or censoring of 25.18 ± 11.43 months, 29 participants (18.6%) progressed. Low GSH (≤10.30 μmol/L; hazard ratio [HR], 3.19; 95% CI, 1.17–8.67) and high 4-HNE (>495.19 pg/mL; HR, 5.01; 95% CI, 2.03–12.35) were associated with progression, with directionally consistent continuous analyses. The combined biomarker score had a 24-month area under the curve (AUC) of 0.820. Adding both biomarkers to eGFR and UACR increased the optimism-corrected Harrell’s concordance index (C-index) from 0.689 to 0.821 (corrected increment, 0.133). Conclusions Lower GSH and higher 4-HNE were associated with progression in early-stage DKD. GSH varied nonmonotonically across severity categories, with the lowest GSH and highest 4-HNE in advanced-stage disease. Joint assessment improved discrimination within this cohort, suggesting that the two biomarkers provide complementary information for assessing progression risk in early-stage DKD.

Frontiers in EndocrinologyVol. 17
Beijing University of Chinese Medicine (CN), Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
National Natural Science Foundation of China, National Key Research and Development Program of China
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon